In an unusual move, a Dutch health insurer has filed a lawsuit accusing AstraZeneca (AZN) of creating an unfair monopoly for its Seroquel antipsychotic with a series of unwarranted patents that raised the cost of the medicine.

In a statement posted earlier this week on its web site, the insurance company Menzis said the drug maker “abused its position” in the marketplace and consequently forced the insurer to pay more for Seroquel because lower-cost generic alternatives were precluded from becoming available. The insurer claims more than $4.7 million in damages.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy